WO2006031930A3 - Modulation of xbp-1 activity for treatment of metabolic disorders - Google Patents

Modulation of xbp-1 activity for treatment of metabolic disorders Download PDF

Info

Publication number
WO2006031930A3
WO2006031930A3 PCT/US2005/032840 US2005032840W WO2006031930A3 WO 2006031930 A3 WO2006031930 A3 WO 2006031930A3 US 2005032840 W US2005032840 W US 2005032840W WO 2006031930 A3 WO2006031930 A3 WO 2006031930A3
Authority
WO
WIPO (PCT)
Prior art keywords
xbp
activity
metabolic disorders
modulation
treatment
Prior art date
Application number
PCT/US2005/032840
Other languages
French (fr)
Other versions
WO2006031930A2 (en
Inventor
Gokhan S Hotamisligil
Laurie H Glimcher
Umut Ozcan
Original Assignee
Harvard College
Gokhan S Hotamisligil
Laurie H Glimcher
Umut Ozcan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, Gokhan S Hotamisligil, Laurie H Glimcher, Umut Ozcan filed Critical Harvard College
Publication of WO2006031930A2 publication Critical patent/WO2006031930A2/en
Publication of WO2006031930A3 publication Critical patent/WO2006031930A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides methods and compositions for modulating the expression, processing, post-translational modification, stability and/or activity of XBP-1 protein, or a protein in a signal transduction pathway involving XBP-1 to treat metabolic disorders, e.g., type II diabetes. The present invention also pertains to methods for identifying compounds that modulate the expression, processing, post-translational modification, and/or activity of XBP-1 protein or a molecule in a signal transduction pathway involving XBP-1.
PCT/US2005/032840 2004-09-15 2005-09-15 Modulation of xbp-1 activity for treatment of metabolic disorders WO2006031930A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61028604P 2004-09-15 2004-09-15
US60/610,286 2004-09-15

Publications (2)

Publication Number Publication Date
WO2006031930A2 WO2006031930A2 (en) 2006-03-23
WO2006031930A3 true WO2006031930A3 (en) 2006-11-02

Family

ID=36060694

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/032840 WO2006031930A2 (en) 2004-09-15 2005-09-15 Modulation of xbp-1 activity for treatment of metabolic disorders

Country Status (1)

Country Link
WO (1) WO2006031930A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012109238A2 (en) 2011-02-07 2012-08-16 President And Fellows Of Harvard College Methods for increasing immune responses using agents that directly bind to and activate ire-1
WO2013134774A1 (en) 2012-03-09 2013-09-12 Cornell University Modulation of breast cancer growth by modulation of xbp1 activity
DK3049521T3 (en) 2013-09-25 2019-04-23 Univ Cornell Compounds for inducing antitumor immunity and methods thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632608B2 (en) * 1999-12-30 2003-10-14 President And Fellows Of Harvard College Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or T cell subset activity by modulation of XBP-1 activity
US20040170622A1 (en) * 2002-08-30 2004-09-02 President And Fellows Of Harvard College Methods and compositions for modulating XBP-1 activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632608B2 (en) * 1999-12-30 2003-10-14 President And Fellows Of Harvard College Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or T cell subset activity by modulation of XBP-1 activity
US20040170622A1 (en) * 2002-08-30 2004-09-02 President And Fellows Of Harvard College Methods and compositions for modulating XBP-1 activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OZCAN ET AL.: "Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes", SCIENCE, vol. 306, 15 October 2004 (2004-10-15), pages 457 - 461 *

Also Published As

Publication number Publication date
WO2006031930A2 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
EP1943219B8 (en) 5-lipoxygenase-activating protein (flap) inhibitors
WO2007047207A3 (en) 5-lipoxygenase-activating protein (flap) inhibitors
WO2007056220A3 (en) 5-lipoxygenase-activating protein (flap) inhibitors
WO2005086661A3 (en) Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
WO2003068944A3 (en) METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1α-
WO2009091815A3 (en) Methods for modulating de novo hepatic lipogenesis by modulating xbp-1 activity
WO2006036994A3 (en) Modulators of crth2, cox-2 and faah
WO2004020610A3 (en) Methods and compositions for modulating xbp-1 activity
ATE542536T1 (en) 3-Ä4-(DIBENZOÄB,FÜÄ1,4ÜOXAZEPINE-11-YL)-PIPERAZI - 1-YLÜ-2,2-DIMETHYL PROPANOIC ACID FOR USE IN THE TREATMENT OF SLEEP DISORDERS
MX2009011949A (en) 5-lipoxygenase-activating protein (flap) inhibitors.
WO2007143689A8 (en) Compositions and methods for modulating vascular development
WO2005117968A3 (en) Compositions and methods comprising an egfl7 antagonist for modulating vascular development
WO2007062078A3 (en) Thrombopoietin activity modulating compounds and methods
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2005037232A3 (en) Methods and compositions for modulating adipocyte function
WO2006113559A3 (en) Methods for modulating bone formation and mineralization by modulating krc activity
WO2008014401A3 (en) Methods for identifying modulators of rgs21 activity, compositions comprising an rgs21 modulator, and methods of use thereof to modulate taste sensation
WO2005112923A3 (en) 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
WO2006031930A3 (en) Modulation of xbp-1 activity for treatment of metabolic disorders
WO2005045428A3 (en) Methods and compositions for modulating apoptosis
WO2009017719A8 (en) Modulators of ccr9 receptor and methods of use thereof
WO2003070169A3 (en) Aminodiphosphonate apolipoprotein e modulators
WO2007132269A8 (en) Dub3 as a cancer therapy target
EA200800890A1 (en) Modulators of hexahydrocycloheptapyrazole cannabinoid
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase